Article info
Extended essay
A world away and here at home: a prioritisation framework for US international patient programmes
- Correspondence to Dr Emily Berkman, Pediatric Critical Care, Seattle Children's Hospital, Seattle, WA 98105, USA; emily.berkman{at}seattlechildrens.org
Citation
A world away and here at home: a prioritisation framework for US international patient programmes
Publication history
- Received August 5, 2020
- Revised February 10, 2021
- Accepted February 13, 2021
- First published March 22, 2021.
Online issue publication
October 18, 2023
Article Versions
- Previous version (22 July 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design
- What is CAR T-cell therapy?
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
- Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
- Cardiotoxicities of novel cancer immunotherapies